The authors of a recent article published in Health Affairs was using “flawed data” in their assessment of rising drug prices, National Pharmaceutical Council CSO and Executive Vice President Robert Dubois writes in a Health Affairs blog post.
The data “likely [led] to flawed results,” Dubois writes, results which made their way across multiple mediums.
In the article, the authors pulled 2008-16 pricing data to find oral brand drugs rose by 9.2 percent, while injectables posted a 15.1-percent increase.
“Unfortunately, the authors used list prices as the source of their assessments,” Dubois writes. “It has been abundantly clear for some time that the list price of a drug greatly differs from the net price, which incorporates discounts and rebates, and that the use of list price leads to misleading results.”
To read the full blog post, click here.